A neoantigen pioneer says its tech is working great. So what wrecked the share price? – Endpoints News
Four months ago, one of the favorite talking points on the biopharma social media wave length was whether Moderna shares $MRNA were priced right or were wildly inflated.
After all, said the naysayers, the company had never actually pushed a treatment to an approval. Did messenger RNA really work, coding cells to make a drug or a vaccine? And how about all that chatter about how secretive they are, or were?
Now, as CEO Stéphane Bancel and the top execs push the company to the forefront of a frantic race to develop the first vaccine to fight against the reignited wildfire spread of Covid-19, all those questions have been magnified along with the stock price.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.